SCHEMBL4356033

SCHEMBL4356033

O=[N+]([O-])c1ccc(Sc2ccc(Cl)cc2)c(CNc2cc(Cl)ccc2O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.49
MEN1 O00255 6/20 0.45
KMT2A Q03164 6/20 0.45
MAPT P10636 6/20 0.45
PDE7A Q13946 7/20 0.44
ALDH1A1 P00352 4/20 0.42
PKM P14618 2/20 0.42
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
AURKA O14965 1/20 0.42
PDPK1 O15530 1/20 0.42
JAK2 O60674 1/20 0.42
GMNN O75496 1/20 0.42
EGFR P00533 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
LYN P07948 1/20 0.42
CHRM2 P08172 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4344437 0.94 MAPT (0.48) NPC1MEN1KMT2AMAPTPDE7A
SCHEMBL4342050 0.88 MAPT (0.44) NPC1MEN1KMT2AMAPTPDE7A
SCHEMBL4353950 0.87 NPC1 (0.46) NPC1MEN1KMT2AMAPTPDE7A
SCHEMBL4347067 0.87 PDE7A (0.45) NPC1MEN1KMT2AMAPTPDE7A
SCHEMBL4354553 0.87 NPC1 (0.44) NPC1MEN1KMT2AMAPTPDE7A
SCHEMBL4346428 0.86 MAPT (0.47) NPC1MEN1KMT2AMAPTPDE7A
SCHEMBL4345719 0.85 NPC1 (0.48) NPC1MEN1KMT2AMAPTPDE7A
SCHEMBL4341851 0.85 MAPT (0.46) NPC1MEN1KMT2AMAPTPDE7A
SCHEMBL4347132 0.84 MAPT (0.43) NPC1MEN1KMT2AMAPTPDE7A
SCHEMBL4351725 0.84 EGFR (0.53) NPC1MEN1KMT2AMAPTPDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 NPC1 815/4885MEN1 2168/4885KMT2A 2096/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 NPC1 1189/4885MEN1 3901/4885KMT2A 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.